علاج ابيضاض الدم ذو الخلايا الشعرية الكلاسيكي عندما لا يحقق إعادة علاج الانتكاس السابق تعداد الدم المستهدف أو الهدأة

References

• In the absence of renal impairment or active infection, therapy should consist of a standard regimen of a purine nucleoside analog (either cladribine or pentostatin).
• Complete remissions have been reported after using the BRAF inhibitor vemurafenib in relapsed and refractory disease.
• Furthermore, newer targeted inhibitors of BRAF (eg, dabrafenib) also show promise in relapsed disease, thus meriting study in larger clinical trials.
• Ibrutinib, a first-in-class oral inhibitor of the Bruton tyrosine kinase has recently been approved for treating patients with relapsed or refractory B-cell malignancies.
• Immunotoxin conjugates have been developed at the National Institutes of Health and are now being investigated in multi-institutional clinical trials (eg, HA-22 or moxetumomab pasudotox).
• These agents have enabled improvement in absolute neutrophils, which shows promise for patients with life-threatening infection.